BIO INX, recognized for its cutting-edge bioinks in the realm of 3D bioprinting, has teamed up with Carl Roth, a renowned entity in the domain of research chemicals and laboratory equipment, entering a new distribution agreement. This strategic partnership represents Carl Roth’s inaugural venture into the 3D bioprinting sphere, aligned with their objective to penetrate the swiftly evolving 3D printing market.
Under this new collaboration, Carl Roth will distribute BIO INX’s comprehensive range of bioinks, thus increasing availability for scientists and researchers globally. This agreement positions Carl Roth to enhance its current 3D printing offerings with state-of-the-art solutions designed for areas such as tissue engineering, regenerative medicine, and other bioprinting fields.
“As a manager for cell culture products, assembling a bioprinting collection for Carl Roth was my primary goal. My academic experience highlighted the vast opportunities and challenges within bioprinting,” shared Lia Heiser. “In support of this research arena, providing superior, reliable bioinks—products I’m confident in and support—was of utmost priority to me.”
With a focus on catering to the diverse demands of the scientific community, BIO INX produces bioinks tailored for various light and extrusion bioprinting methods while emphasizing clinical translation, exemplified by their GMP-like ink offerings. Partnering with Carl Roth ensures that researchers receive dependable logistics and trustworthy assistance as they pioneer new scientific innovations.
Jasper Van Hoorick, CEO of BIO INX, remarked, “Joining forces with Carl Roth furnishes BIO INX with a remarkable opportunity to streamline our logistics and sales network via a global leader in distributing research chemicals and laboratory supplies. Carl Roth’s trusted platform brings our bioinks nearer to clinical implementation through streamlined logistics and dependable partnerships.”
This alliance underlines Carl Roth’s strategic endeavor into bioprinting, emphasizing the company’s dedication to maintaining a leading position in technological progress. Leveraging Carl Roth’s extensive distribution infrastructure and BIO INX’s prowess in biomaterials, the partnership aims to foster swift progress in both research-driven and clinical bioprinting applications.
Originating from Ghent University and the Vrije Universiteit Brussel, BIO INX stands as a trailblazer in the development of bioinks for 3D bioprinting, with a steadfast commitment to pushing healthcare innovation. With a diverse array of bioinks for high-resolution extrusion and light-based printing technologies, BIO INX asserts its leadership in the bioink market for diverse 3D bioprinting technologies.